您的位置: 首页 > 2024年4月 第55卷 第4期 > 文字全文
2023年7月 第38卷 第7期11
目录

MRI、TRUS联合血清PSA对前列腺癌的诊断价值

Diagnostic value of MRI,TRUS combined with serum PSA in prostate cancer

来源期刊: 广州医药 | 365-369 发布时间:2024-05-17 收稿时间:2025/11/13 18:49:03 阅读量:22
作者:
关键词:
磁共振成像经直肠超声前列腺特异性抗原前列腺癌诊断效能
magnetic resonance imagingtransrectal ultrasonographyprostate-specific antigenprostate cancerdiagnostic performance
DOI:
10.3969/j.issn.1000-8535.2024.04.005
收稿时间:
2023-08-02 
修订日期:
 
接收日期:
 
引用总数:
1  
目的 研究磁共振成像(MRI)、经直肠超声(TRUS)结合血清前列腺特异性抗原(PSA)诊断前列腺癌诊断的应用价值。方法 收集2020年1月—2023年1月前在武穴市第一人民医院检查的疑似前列腺癌患者140例,均给予MRI、TRUS检查,并进行血清PSA水平检测,以患者手术病理结果为金标准,观察单一MRI、TRUS、血清PSA及联合诊断时漏诊、误诊情况,进行一致性分析,计算各项单一诊断及联合诊断的诊断灵敏度、特异度、准确率。结果 经手术病理结果证实为前列腺癌81例,非前列腺癌59例,前列腺癌患者血清PSA水平高于非前列腺癌患者(P<0.05);单一MRI、TRUS或PSA诊断前列腺癌与手术病理结果的一致性一般(Kappa=0.641、0.624、0.536,均P<0.001),联合诊断与手术病理结果的一致性较好(Kappa=0.906,P<0.001);联合诊断的灵敏度、特异度、准确率为高于单一MRI、TRUS、血清PSA及各诊断方式两两联合(P<α,α=0.007)。结论 前列腺癌诊断中单一MRI、TRUS、血清PSA诊断均存在漏诊、误诊风险,联合诊断可弥补单一诊断的不足,提高前列腺癌患者的诊断准确率。
Objective To study the application value of magnetic resonance imaging(MRI),transrectal ultrasound(TRUS)combined with serum prostate-specific antigen(PSA)in the diagnosis of prostate cancer.Methods A total of 140 patients with suspected prostate cancer who were examined at Wuxue First People's Hospital from January 2020 to January 2023 were enrolled.MRI and TRUS examinations were performed,and serum PSA levels were tested.The surgical pathology results of the patients were used as the gold standard.The missed diagnosis and misdiagnosis in single MRI,TRUS,serum PSA and combined diagnosis were observed,consistency was analyzed,and the diagnostic sensitivity,specificity,and accuracy of each single diagnosis and combined diagnosis were calculated.Results There were 81 cases of prostate cancer and 59 cases of non-prostate cancer confirmed by surgical pathology results.The serum PSA level of prostate cancer patients was higher than that of non-prostate cancer patients(P<0.05).The difference between the diagnosis of prostate cancer by single MRI,TRUS or PSA and the results of surgical pathology was with general consistency(Kappa=0.641,0.624,0.536,all P<0.001),and the consistency of combined diagnosis and surgical pathology results was good(Kappa=0.906,P<0.001).The sensitivity,specificity,and accuracy of combined diagnosis were higher than single MRI,TRUS,serum PSA and the combination of two diagnostic methods(P<α,α=0.007).Conclusions In the diagnosis of prostate cancer,single MRI,TRUS and serum PSA diagnosis all have risks of missed diagnosis and misdiagnosis.Combined diagnosis can make up for the shortcomings of single diagnosis and improve the diagnostic accuracy of prostate cancer.
1、 盛国玉,王昌生,岳晓荷,等.前列腺癌患者TRUS检查表现结合β2微球蛋白检测与其临床分期及疾病危险度的关系[J].国际泌尿系统杂志,2021,41(6):972-975. 盛国玉,王昌生,岳晓荷,等.前列腺癌患者TRUS检查表现结合β2微球蛋白检测与其临床分期及疾病危险度的关系[J].国际泌尿系统杂志,2021,41(6):972-975.
2、 金鹏飞,包婕,乔晓梦,等.基于PI-RADS V2.1评估双参数和多参数MRI对外周带临床显著性前列腺癌的诊断价值[J].放射学实践,2022,37(8):1000-1005. 金鹏飞,包婕,乔晓梦,等.基于PI-RADS V2.1评估双参数和多参数MRI对外周带临床显著性前列腺癌的诊断价值[J].放射学实践,2022,37(8):1000-1005.
3、 孟凡祺,黄浩,齐旭红,等.基于简化版前列腺影像报告和数据系统评分标准的双参数MRI诊断方案对前列腺癌的诊断价值[J].实用放射学杂志,2023,39(5):764-768. 孟凡祺,黄浩,齐旭红,等.基于简化版前列腺影像报告和数据系统评分标准的双参数MRI诊断方案对前列腺癌的诊断价值[J].实用放射学杂志,2023,39(5):764-768.
4、 杨莉月,耿承军,杨晓亮.MRI多参数成像技术在前列腺癌患者诊断中的应用[J].中国实验诊断学,2017,21(11):1907-1911. 杨莉月,耿承军,杨晓亮.MRI多参数成像技术在前列腺癌患者诊断中的应用[J].中国实验诊断学,2017,21(11):1907-1911.
5、 靳洪亮,吴瑕.动态对比增强MRI定量分析在前列腺癌鉴别诊断及病理分级中的应用价值[J].山东医药,2020,60(1):78-81. 靳洪亮,吴瑕.动态对比增强MRI定量分析在前列腺癌鉴别诊断及病理分级中的应用价值[J].山东医药,2020,60(1):78-81.
6、 段万里,胥博愈,任伟,等.前列腺特异性抗原联合炎性细胞计数、年龄对前列腺癌的诊断价值[J].现代泌尿外科杂志,2021,26(6):505-509. 段万里,胥博愈,任伟,等.前列腺特异性抗原联合炎性细胞计数、年龄对前列腺癌的诊断价值[J].现代泌尿外科杂志,2021,26(6):505-509.
7、 韩丽莹,何冠勇,喻晴,等.MRI多模型扩散加权成像及PSA相关指标诊断前列腺癌的价值[J].中国CT和MRI杂志,2023,21(3):121-123,152. 韩丽莹,何冠勇,喻晴,等.MRI多模型扩散加权成像及PSA相关指标诊断前列腺癌的价值[J].中国CT和MRI杂志,2023,21(3):121-123,152.
8、 王晓岩,许新征,尉迟今新,等.TRUS引导下前列腺穿刺活检联合PSA水平变化在诊断前列腺癌中的价值[J].癌症进展,2017,15(8):894-896,906. 王晓岩,许新征,尉迟今新,等.TRUS引导下前列腺穿刺活检联合PSA水平变化在诊断前列腺癌中的价值[J].癌症进展,2017,15(8):894-896,906.
9、 周柱玉,李金,郑红,等.多模态经直肠超声与MRI诊断前列腺癌的对比分析[J].临床泌尿外科杂志,2020,35(10):795-799. 周柱玉,李金,郑红,等.多模态经直肠超声与MRI诊断前列腺癌的对比分析[J].临床泌尿外科杂志,2020,35(10):795-799.
10、 刘毅豪,黄智峰,吴松,等.血清PSA、PSAD和HMGB1水平检测对老年前列腺癌的诊断价值[J].海南医学,2021,32(12):1527-1530. 刘毅豪,黄智峰,吴松,等.血清PSA、PSAD和HMGB1水平检测对老年前列腺癌的诊断价值[J].海南医学,2021,32(12):1527-1530.
11、 于立超,黄志鹏,王平.实时超声造影及MRI联合经直肠超声对前列腺癌穿刺检出率的对比研究[J].中国CT和MRI杂志,2023,21(6):144-146. 于立超,黄志鹏,王平.实时超声造影及MRI联合经直肠超声对前列腺癌穿刺检出率的对比研究[J].中国CT和MRI杂志,2023,21(6):144-146.
12、 FOSB?L M ?,KURBEGOVIC S,JOHANNESEN H H,et al.Urokinase-type plasminogen activator receptor(uPAR)PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness:Comparison with gleason score in a prospective phase 2 clinical trial[J].J Nucl Med,2021,62(3):354-359. FOSB?L M ?,KURBEGOVIC S,JOHANNESEN H H,et al.Urokinase-type plasminogen activator receptor(uPAR)PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness:Comparison with gleason score in a prospective phase 2 clinical trial[J].J Nucl Med,2021,62(3):354-359.
13、 牛犇,曹辉.MRI联合经直肠超声靶向穿刺在前列腺癌中的应用[J].影像科学与光化学,2023,41(1):6-10. 牛犇,曹辉.MRI联合经直肠超声靶向穿刺在前列腺癌中的应用[J].影像科学与光化学,2023,41(1):6-10.
14、 石锋,舒松,吴明,等.MRI联合TRUS检查对前列腺癌穿刺检出率的影响[J].影像科学与光化学,2020,38(6):1010-1013. 石锋,舒松,吴明,等.MRI联合TRUS检查对前列腺癌穿刺检出率的影响[J].影像科学与光化学,2020,38(6):1010-1013.
15、 任靖文,喻婷,罗光恒,等.MRI联合人工智能在前列腺癌诊断中的应用进展[J].中国CT和MRI杂志,2023,21(3):184-186. 任靖文,喻婷,罗光恒,等.MRI联合人工智能在前列腺癌诊断中的应用进展[J].中国CT和MRI杂志,2023,21(3):184-186.
1、郝苑苑,王君,黄茜.经直肠超声联合超声造影对前列腺低回声病灶良恶性诊断的价值[J].临床荟萃,2024,39(07):635-639. 郝苑苑,王君,黄茜.经直肠超声联合超声造影对前列腺低回声病灶良恶性诊断的价值[J].临床荟萃,2024,39(07):635-639.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录